Nutriband Stock Price, News & Analysis

Nutriband Inc. (NASDAQ:NTRB) announced its subsidiary, 4P Therapeutics, completed a Phase 1b clinical study for Sorrento Therapeutics (NASDAQ:SRNE). Results will be presented at the American College of Rheumatology (ACR) Convergence 2022 on November 13, 2022, highlighting significant improvements in rheumatoid arthritis disease measures at 50% of the standard dose. The study emphasizes the potential of the Sofusa lymphatic delivery platform for treating autoimmune diseases and showcases 4P Therapeutics' capabilities in advancing drug delivery products.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to speak at the 2023 Transdermal and Microneedle Conference in London on January 23-24. CEO Gareth Sheridan will present on improving transdermal technologies to reduce the abuse potential of medications, referencing their AVERSA technology. Additionally, COO Dr. Alan Smith will participate in a panel discussion on microneedles as a drug delivery tool. Other notable participants include representatives from Merck, GSK, and Sanofi.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced progress in collaboration with Kindeva Drug Delivery for their AVERSA™ Fentanyl patch, an abuse-deterrent transdermal system. Recent studies confirm that Nutriband's aversive coating can be produced with standard manufacturing processes, crucial for product development. The product has a projected peak annual sales potential of $80M - $200M within five years post-launch. Nutriband aims to finalize product configuration and transfer technology to Kindeva's commercial facility in California.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) has initiated the application process for a dual listing on Upstream, a digital trading app. This move aims to tap into a global investor base, facilitating trades in USDC digital currency and traditional payment methods. CEO Gareth Sheridan emphasized that this listing could enhance shareholder value and liquidity while expanding access to international markets. Approval from MERJ Exchange is pending; however, Nutriband's adherence to NASDAQ standards is sufficient for compliance. The company is known for developing abuse deterrent technologies for pharmaceuticals.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) will be featured on the RedChip Money Report airing on Bloomberg TV this Saturday, September 17, at 7 p.m. ET. The interview will highlight various aspects of the company, including expanded patents, commercialization plans, and Q2 revenue results. Chairman & President Serguei Melnik will discuss these developments, which could pique investor interest. Bloomberg TV reaches approximately 73 million homes across the U.S.

Nutriband Inc. (NASDAQ:NTRB) reported significant growth in its Q2 2022 financial results, achieving record quarterly revenue of $0.5 million, a 113% increase year-over-year. Over six months, revenue rose 44%. The company received a favorable court ruling enabling the cancellation of 1.2 million shares, representing 15% of outstanding shares at the time. Nutriband continues to expand its AVERSA™ intellectual property, now protected in 45 countries. However, net loss increased to $1.0 million from $0.5 million year-over-year.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the effective date of a 7:6 forward stock split that took place on August 12, 2022, with a record date of August 15, 2022. Each holder of 6 shares of common stock received 7 shares, with no change to the per-share par value. The stock split will not affect stockholders' equity percentages. Additionally, the exercise price of outstanding warrants will be adjusted to $6.43 per share, corresponding to the stock split ratio. Book-entry holders do not need to take action, while those seeking stock certificates will receive further instructions.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a Notice of Allowance for its patent application from the Canadian Intellectual Property Office. This patent is crucial for the company's AVERSA™ transdermal abuse deterrent technology, enhancing intellectual property protection across North America.

The AVERSA™ technology aims to reduce drug misuse and abuse while ensuring accessibility for patients in need. The lead product, AVERSA™ Fentanyl, is projected to achieve peak annual sales of $80M - $200M. Nutriband's patent portfolio spans multiple countries, bolstering its market position.

Nutriband Inc. (NTRB, NTRBW) announced a 7:6 forward stock split effective at 12:01 AM on August 15, 2022. Shareholders will receive seven shares for every six shares held, maintaining the par value. CEO Gareth Sheridan emphasized the company's commitment to creating shareholder value following recent milestones. Nutriband is focused on developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing its AVERSA technology. The company acknowledges various risks involved in its development and regulatory processes.